Nanoparticle-based immunotherapy: state of the art and future perspectives.

Clicks: 414
ID: 105730
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 4 articles by views in expert review of clinical immunology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
: For several years now, medicine has been benefiting from the contribution of nanoparticles (NPs) technology for both diagnosis and therapy. They can be used as adjuvants, being capable of immune-modulating activity, or as carriers for molecules to be transported to a specific target, eventually loaded with specific ligands favoring specific uptake.: The review focuses on experimental use of NPs as adjuvants/carriers for allergen immunotherapy (AIT). Human clinical trials conducted so far are discussed.: Results of experimental studies and recent clinical trials support the use of NPs as carrier/adjuvant in AIT. Comparisons between NP-based and classical AIT are needed, to show the usefulness of the NP-based approach. However, there are still unsolved problems: the persistence of non-degradable NPs with possible toxicological consequences, and the formation of the protein corona around the NPs, which could alter their activity and fate. Virus-like particles seem the most promising NPs for allergy treatment, as for other vaccines. Over the next decade NP-based AIT will be largely used to treat allergic disorders.
Reference Key
di-gioacchino2020nanoparticlebasedexpert Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Di Gioacchino, Mario;Petrarca, Claudia;Gatta, Alessia;Scarano, Gilda;Farinelli, Anila;Della Valle, Loredana;Lumaca, Arianna;Del Biondo, Pietro;Paganelli, Roberto;Di Giampaolo, Luca;
Journal expert review of clinical immunology
Year 2020
DOI
10.1080/1744666X.2020.1762572
URL
Keywords
nanoparticles adjuvant allergy liposomes allergen immunotherapy carriers virus-like particles nanopolymers

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.